Open AccessDevelopment of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: A possible challenge to elimination program in India
Author(s) -
Vidya Nand Rabi Das,
Krishna Pandey,
Dharmendra Singh,
C Forwood,
Chandra Shekhar Lal,
Pradeep Das
Publication year - 2013
Publication title -
journal of postgraduate medicine/journal of postgraduate medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.405
H-Index - 52
eISSN - 0972-2823
pISSN - 0022-3859
DOI - 10.4103/0022-3859.118046
Subject(s) - medicine , visceral leishmaniasis , leishmaniasis , dermatology , amphotericin b , leishmania donovani , antifungal , immunology
We report two cases, one male (33 years) and a female (14 years), that developed Post-Kala-azar Dermal Leishmaniasis (PKDL) after successful treatment for visceral leishmaniasis (VL) or Kala-azar with AmBisome, the lipid complex of Amphotericin B. Both cases presented with hypo-pigmented macular lesions all over the body. The patients responded well to AmBisome after treatment with three courses. This first ever case report from India indicates that possibly there is no effective drug for VL until date, which can prevent post-treatment development of PKDL.